IGF-1 (Insulin-Like Growth Factor 1)
Also known as: Insulin-Like Growth Factor 1, IGF-1, Somatomedin C, MGF (mechano growth factor, an isoform)
Endogenous polypeptide growth factor / anabolic hormone
Looking for the IGF-1 blood test? See IGF-1 blood test.
What it is
IGF-1 is a natural growth factor the body makes in response to growth hormone; synthetic versions are used by athletes for muscle building and are studied for neurological and metabolic diseases. A pharmaceutical form is FDA-approved for rare severe growth failure in children. Prescription-only for that indication; banned by WADA in sport.
The scientific side
IGF-1 is described as the principal mediator of growth hormone (GH), playing a crucial role in promoting cell growth and differentiation in childhood and exerting anabolic effects in adults. IGF-1 binds specifically to the type 1 IGF receptor (IGF-1R), transmitting intracellular signals through insulin receptor substrate (IRS) and Src homology collagen (Shc) proteins, which activate two major pathways: the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and the mitogen-activated protein kinase (MAPK)/ERK pathway. These downstream cascades regulate cell proliferation, survival, differentiation, apoptosis, and metabolism (PMID 33557137; PMID 34452353). The bioavailability of circulating IGF-1 is regulated by six IGF-binding proteins (IGFBPs), which bind approximately 98% of all circulating IGF-1 with affinity equal to or greater than that of IGF-1R itself. IGF-1 is produced mainly in the liver by GH signaling and also acts as an autocrine/paracrine factor in multiple tissues (PMID 35297369; PMID 41153350). Its actions encompass regulation of cell growth, differentiation, energy metabolism, immune modulation, and neuroprotection (PMID 41153350; PMID 36503467; PMID 34452353).
Class: Endogenous polypeptide growth factor / anabolic hormone
Administration & storage
- Administration
- Subcutaneous injection (local administration at wound site in mouse model) (PMID: 33895582)
- Storage
- No abstracts in the reviewed literature explicitly describe storage conditions for IGF-1.
- Cautions
- IGF-1 is described as a popular doping agent in sport and has featured in many high-profile doping cases; its detection is complicated by IGFBPs which significantly reduce immunoreactive IGF-1 levels in samples.,The existence of multiple IGF-binding proteins (IGFBPs) and IGFBP-related proteins means that total versus free IGF-1 measurements can yield discordant results, complicating interpretation of assay findings.,IGF-1 signaling has been implicated in the promotion of multiple cancers including prostate, breast, hepatocellular, colorectal, and multiple myeloma; elevated IGF-1 was associated with poor prognosis in HCC (PMID: 35297369; PMID: 41184420; PMID: 34208601).,Congenital IGF-1 deficiency (Laron syndrome) is associated with protection from cancer, highlighting the oncogenic potential of IGF-1 signaling at elevated levels.,No human pharmacokinetic, dosing safety, or clinical trial safety data for exogenously administered IGF-1 were present in the reviewed abstracts. Sterile technique is essential for any injectable compound.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. Note: One abstract mentions 'FDA has recently approved a drug against ADPKD' in a different context, but no abstract explicitly states FDA approval…
IGF-1 is described as 'a popular doping agent in sport' that 'has featured in many high-profile doping cases in recent years', but the abstract does not explicitly state WADA prohibition status — requires manual…
Not stated in reviewed literature — requires manual verification
What it's studied for
- Growth and height regulation in childhood and adulthood Mixed
- Mendelian randomization showed a 1 SD increase in IGF-1 confers 0.09 SD taller adult height. Both measured IGF-1 levels at ages 7–8 years and a genetic risk score for IGF-1 were positively associated with height at ages 7–17 years. PMID 41017432 De La Barrera et al., J Clin Endocrinol Metab (2026)
- IGF-1 levels in constitutional advancement of growth and puberty (CAGP) are above average, while in constitutional delay (CDGP) they are below average. IGF-1 is proposed as a decisive factor for pubertal onset via GnRH brake release. PMID 35331614 Papadimitriou et al., Trends Endocrinol Metab (2022)
- Neuroprotection and neurological disease (Parkinson's disease, ASD, neuroapoptosis) Mixed
- In 405 early-stage drug-naive PD patients followed over 10 years, higher baseline serum IGF-1 was significantly associated with slower progression of anxiety symptoms (IGF-1 × time interaction: β = −0.003, p = 0.038). PMID 41905437 Chen et al., Prog Neuropsychopharmacol Biol Psychiatry (2026)
- In 129 PD patients, serum IGF-1 levels were significantly associated with NMSS scores, general cognitive function, information processing speed, executive function, and fatigue. PMID 39467934 Gu et al., Neurol Sci (2025)
- In human SH-SY5Y neuroblastoma cells, IGF-1 treatment restored AKT phosphorylation, reduced pro-apoptotic markers (p53, cleaved caspase-3), and significantly decreased apoptotic cell death and DNA fragmentation induced by sodium arsenite via reactivation of the PI3K/AKT pathway. In vitro study. PMID 41534734 Elsayed, Comp Biochem Physiol Toxicol Pharmacol (2026)
- IGF-1 was increased in ASD serum compared to controls and was correlated with age and CARS scores in children aged 5–15 years. PMID 35962006 Robinson-Agramonte et al., Sci Rep (2022)
- Review: IGF-1 and its isoforms (IGF-1Ea and IGF-1Eb/Ec [MGF]) represent a promising therapeutic approach for nerve repair, given proliferative and anti-apoptotic capacities on neurons under adverse environmental conditions including hypoxia-ischemia, inflammation, and oxidative stress. PMID 36503467 Sha et al., Curr Protein Pept Sci (2023)
- Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) Mixed
- IGF-1 suppressed antigen processing and presentation machinery and upregulated PD-L1 (CD274) via IGF-1R/AKT/ERK-dependent signaling in prostate cancer cells, suggesting an immunosuppressive mechanism underlying PCa resistance to immunotherapy. PMID 41184420 Nandakumar et al., Sci Rep (2025)
- In metastatic prostate cancer patients (CHAARTED trial), a higher IGF-1:IGF-BP1 ratio at baseline and at 6 months was associated with improved overall survival in both ADT and ADT+docetaxel groups (baseline HR = 0.77, p = 0.026 for ADT group). PMID 37671811 Ravi et al., Endocr Relat Cancer (2023)
- Patients with Laron syndrome (congenital IGF-1 deficiency) do not develop cancer, emphasizing the central role of the GH-IGF-1 system in cancer biology. PMID 37343154 Laron & Werner, Endocr Relat Cancer (2023)
- Review: IGF-1 activates PI3K/Akt/mTORC and Raf/MAPK pathways, glucose transporters, and glycolytic enzymes in colorectal cancer, potentially promoting the Warburg effect. PMID 34208601 Kasprzak, Int J Mol Sci (2021)
- In HCC patients with T2DM, higher IGF-1 expression was detected compared to those without T2DM. In vitro, IGF-1 promoted autophagy, inhibiting apoptosis and inducing growth and migration of HepG2 cells. Elevated IGF-1 was associated with poor prognosis in HCC patients. PMID 35297369 Shan et al., Ann Hepatol (2022)
- IGF-1 enhanced acquisition of mesenchymal features in multiple myeloma cells in a time-dependent manner, promoting migration, invasion, and colony formation via PI3K/Akt signaling. PMID 32142767 Peng et al., Life Sci (2020)
- Meta-analysis: gastric cancer patients had significantly lower serum IGF-1 levels than healthy subjects (WMD = −26.21 ng/mL, 95% CI: −45.58 to −6.85, p = .008). PMID 34469629 Liu et al., Int J Clin Pract (2021)
- Metabolic health — fatty liver disease (MASLD), insulin resistance, PCOS Mixed
- Review: Several clinical studies reported a relationship between decreased IGF-1 and progression of MASLD in both children and adults. IGF-1 levels could serve as a non-invasive biomarker for monitoring disease progression and therapeutic response. PMID 41796683 Srimanus et al., Biochim Biophys Acta Mol Basis Dis (2026)
- Review: IGF-1 plays an essential role in PCOS pathogenesis through its functions in regulating cell proliferation, metabolic processes, and reducing inflammatory responses via metabolic inflammation. PMID 38941670 Li et al., Int Immunopharmacol (2024)
- Bone health and fracture risk (beta-thalassemia major) Human observational
- In 30 adult males with beta-thalassemia major, serum IGF-1 was significantly lower in patients with vertebral fractures vs. those without (p = 0.005). IGF-1 ≤50.0 ng/dL was associated with vertebral fractures (sensitivity 83.3%, specificity 75.0%) and predictive of GH deficiency. PMID 38526837 Costanzo et al., J Endocrinol Invest (2024)
- In 81 adult beta-thalassemia major patients, 94.4% of GHD and 93.6% of non-GHD patients had IGF-1 levels below the reference range. GHD was associated with higher BMI and worse lipid profile. PMID 35305249 Gagliardi et al., J Endocrinol Invest (2022)
- Exercise physiology and physical performance Mixed
- Meta-analysis of 21 studies: acute endurance exercise significantly affected total IGF-1 (p = .01, ES = 0.81) and resistance exercise affected total IGF-1 (p = .003, ES = 0.46), but neither affected free IGF-1. IGF-1 serum concentrations are altered by exercise type under conditions that are not well-defined. PMID 32259791 de Alcantara Borba et al., J Phys Act Health (2020)
- In a 12-week RCT of pre-menopausal women doing resistance and interval training, post-exercise whey protein supplementation had little effect on IGF-1 (no significant change: CON −6.0 ± 27.7 µg/L, PRO −2.1 ± 27.8 µg/L, p = 0.920). IGF-1 was not associated with any outcome measure. PMID 40573144 Murray et al., Nutrients (2025)
- Wound healing and tissue regeneration Animal studies only
- In a mouse model of scalding, local administration of IGF-1-expressing placenta-derived MSCs via subcutaneous injection increased wound contraction and healing rates, suppressed inflammation (decreased TNF-α, IL-1β, IL-6), increased VEGF, and decreased TGF-β1, collagen I and III. PMID 33895582 Cheng et al., J Surg Res (2021)
- In neonatal mice, macrophage-derived IGF-1 promotes VEGF expression, endothelial cell proliferation, and protects against experimental NEC. Exogenous IGF-1 preserved intestinal microvascular density and protected against experimental NEC. PMID 35388142 Yan et al., Commun Biol (2022)
- Skin aging and dermatological conditions (androgenetic alopecia, keloid, skin proteoglycan regulation) Mixed
- IGF-1 treatment of primary human dermal fibroblasts increased biglycan and decorin protein levels by enhancing translation and decreasing ADAMTS5-mediated degradation, suggesting a role in skin aging. PMID 33573338 Lee et al., Int J Mol Sci (2021)
- In AGA patients, miR-221 (promoted by androgen receptor) suppresses IGF-1 expression, leading to inactivation of MAPK and PI3K/AKT pathways in dermal papilla and dermal sheath cells, impairing hair growth. PMID 37496996 Li et al., Int J Biol Sci (2023)
- Cardiovascular and endothelial biology (atherosclerosis, systemic sclerosis) Mixed
- In human aortic endothelial cells, FOXP1 transcriptionally activated IGF-1 expression, and both FOXP1 and IGF-1 overexpression mitigated ox-LDL-induced cellular senescence and NLRP3 inflammasome activation. PMID 39585426 Deng et al., Biogerontology (2024)
- Serum IGF-1 levels were significantly elevated in early/mild systemic sclerosis compared to pre-clinical stage (anti-centromere antibody-positive patients), suggesting a role in disease development from pre-clinical to early SSc. PMID 32013651 Tabata et al., Mod Rheumatol (2021)
- Polycystic kidney disease (ADPKD) Animal studies only
- PAPP-A (a metalloproteinase increasing local IGF-1 bioactivity) was highly induced in ADPKD mouse kidneys and human ADPKD cystic fluid. Pappa deficiency inhibited cyst development. A monoclonal antibody blocking PAPP-A proteolytic activity ameliorated ADPKD in vivo and ex vivo. PMID 31990681 Kashyap et al., JCI Insight (2020)
- Postoperative delirium (biomarker) Human observational
- Meta-analysis: low preoperative IGF-1 levels (7 studies) are significantly associated with post-operative delirium specifically in abdominal surgical samples. PMID 34536657 Adamis et al., Arch Gerontol Geriatr (2021)
- Fibromyalgia (biomarker) Human observational
- Meta-analysis of 12 studies (512 FM patients, 308 controls): after sensitivity analysis and publication bias adjustment, IGF-1 levels were significantly lower in FM patients (SMD = −0.458 to −0.513), suggesting a potential pathogenic role. PMID 40153319 Lee & Song, Clin Exp Rheumatol (2025)
- Schizophrenia (biomarker and treatment response) Human observational
- IGF-1 levels were lower in treatment-sensitive (remission) schizophrenia patients than in both treatment-resistant patients and healthy controls. IGF-1, LDL, and age of disease onset were significantly associated with treatment resistance in a regression model. PMID 34116443 Yesilkaya et al., J Psychiatr Res (2021)
- Acromegaly monitoring and treatment assessment Human observational
- In 90 acromegaly patients, GH/IGF-1 discordance rate was 52.2% (cutoff 1 µg/L) and 35.6% (cutoff 2.5 µg/L). Both single fasting GH and mean of 3 GH measurements were poor predictors of IGF-1 normalization (AUC = 0.611 and 0.645). PMID 33236108 Campana et al., J Clin Endocrinol Metab (2021)
- Pediatric metabolic abnormalities and hypertension (biomarker) Human observational
- In 586 children and adolescents, lower IGF-1 levels were significantly associated with increased hypertension risk. Compared to the highest IGF-1 quartile, adjusted OR for hypertension in quartile 1 was 6.99 (p < 0.05). PMID 41039295 Zhao et al., BMC Pediatrics (2025)
- In 588 Chinese children and adolescents, higher IGF-1 (Q4 OR 0.24, 95% CI 0.11–0.51) and IGFBP-3 (Q4 OR 0.38, 95% CI 0.18–0.76) levels were associated with lower odds of metabolic abnormalities. PMID 40538800 Zhao et al., Front Endocrinol (2025)
- Retinal and ocular biology (RPE metabolism, Müller glial cell glucose uptake, posterior capsular opacification) In vitro only
- In ARPE-19 cells, IGF-1 favored PKM2 dimerization, reducing PKM2 activity and leading to altered cellular energy status coupled with reduced oxidative stress. Klotho pre-treatment mitigated IGF-1 signal and its effect on mitochondrial function. PMID 39769402 Ravera et al., Int J Mol Sci (2024)
- IGF-1 produced GLUT1 translocation to the plasma membrane in Müller glial cells via MAPK/ERK and PI3K/Akt pathways, and LRP1 mediated this process; LRP1 knockdown impaired IGF-1-induced GLUT1 expression and glucose uptake. PMID 33637845 Actis Dato et al., Sci Rep (2021)
- Effects of tamoxifen and metformin on IGF-1 levels Mixed
- Meta-analysis of RCTs: tamoxifen administration significantly reduced IGF-1 levels in women with breast cancer or at risk (WMD: −14.41 µg/L, 95% CI: −24.23 to −4.60, p = 0.004). PMID 38608792 Li et al., Exp Gerontol (2024)
- Meta-analysis of 11 RCTs: overall non-significant decline in IGF-1 with metformin (WMD: −8.292 ng/ml, p = 0.174). In children, intervention <12 weeks significantly reduced IGF-1 (WMD: −55.402 ng/ml). In adults >18 years, metformin significantly increased IGF-1 (WMD: 15.125 ng/ml). PMID 31816435 Yang et al., Pharmacol Res (2020)
- Pomegranate extract and IGF-1 in older adults Human RCT
- In a double-blind RCT of 72 participants aged 55–70 years, pomegranate extract (740 mg/day for 12 weeks) significantly increased serum IGF-1 levels at week 12 (F = 3.43, p = 0.04) compared to placebo. No significant effects on telomere length were noted. PMID 41010500 Farhat et al., Nutrients (2025)
Safety signals
- IGF-1 signaling promotes prostate cancer immune evasion by downregulating antigen processing machinery and upregulating PD-L1 checkpoint via IGF-1R/AKT/ERK signaling, potentially facilitating immunotherapy resistance. PMID 41184420
- Elevated IGF-1 was associated with poor prognosis in hepatocellular carcinoma patients, especially when accompanied by type 2 diabetes; IGF-1 promoted autophagy, inhibiting apoptosis and inducing growth and migration in liver cancer cells. PMID 35297369
- Congenital absence of IGF-1 (Laron syndrome) protects against cancer development, suggesting that sustained elevated IGF-1 signaling is oncogenic across multiple cancer types. PMID 37343154
- IGF-1 is described as a popular doping agent in sport with many high-profile doping cases; detection is complicated by IGFBPs reducing immunoreactive IGF-1 levels. PMID 33557137
- IGF-1 upregulated PD-L1 (CD274) in prostate cancer cells and was associated with higher CD274 expression in tumors with elevated IGF-1 and IGFBP5 in TCGA data. PMID 41184420
- In ARPE-19 retinal pigment epithelial cells, IGF-1 altered cellular energy status and reduced oxidative stress response via PKM2 dimerization, which may participate in the pathogenesis of retinal degenerative diseases. PMID 39769402
- IGF-1 promoted IGF-1-driven invasion and migration in triple-negative breast cancer cells via PI3K/Akt/β-catenin axis activation. PMID 41294378
- The IGF-1/IGF-1R signaling pathway is associated with TNBC pathophysiology and therapy resistance; combination therapy strategies are being explored to overcome this resistance. PMID 39357179
- IGF-1 promoted multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition, enhancing migration, invasion, and colony formation. PMID 32142767
- In chronic inflammatory conditions, inhibition of the GH-IGF-1 axis contributes to skeletal muscle atrophy and cachexia. PMID 34452353
- In prolactinoma patients treated with cabergoline, IGF-1 levels showed significant reductions with longer treatment duration (≥18 months) and higher cumulative doses (≥60 mg); clinical significance of within-range IGF-1 reductions is uncertain. PMID 41108835
Contraindications
- No explicit contraindications for exogenous IGF-1 administration are stated in the reviewed abstracts. The reviewed literature does not address clinical contraindications. PMID 33557137
Protocol
20-40 mcg subcutaneous injection, once daily. Cycle: 4-6 weeks on, 4 weeks off.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Subcutaneous injection (local administration at wound site) in mouse model | IGF-1-expressing hPMSCs administered; specific IGF-1 dose not quantified in abstract | Not specified in abstract | animal | Research PMID 33895582 |
| Not specified in abstract (in vivo mouse model) | Exogenous IGF-1 (specific dose not quantified in abstract) | Not specified in abstract | animal | Research PMID 35388142 |
| Oral (capsule) | Pomegranate extract 740 mg/day (IGF-1 not directly administered; this is the intervention dose that elevated serum IGF-1) | 12 weeks | human | Research PMID 41010500 |
| Oral | Whey protein 24 g post-exercise (PRO group) vs. 3 g (CON group); IGF-1 not directly administered | 12 weeks | human | Research PMID 40573144 |
| subcutaneous injection | 20-40 mcg | once daily · 4-6 weeks on, 4 weeks off | bodybuilders and advanced biohackers seeking muscle hypertrophy and recovery | [Community] |
| intramuscular injection | 20-40 mcg | once daily, post-workout · 4-6 weeks on, 4 weeks off | bodybuilders targeting site-specific muscle hypertrophy | [Community] |
| subcutaneous injection | 10-20 mcg | once daily · 4-6 weeks | intermediate biohackers, beginners to IGF-1, anti-aging users | [Community] |
| subcutaneous injection | 50-100 mcg | once daily · 4 weeks on, 4 weeks off | advanced bodybuilders and high-dose performance users | [Community] |
| subcutaneous injection | 20-40 mcg | twice daily (morning and post-workout) · 4-6 weeks on, 4 weeks off | advanced bodybuilders running split-dose IGF-1 protocols | [Community] |
| subcutaneous injection | 20-40 mcg | once daily · 8-12 weeks | biohackers stacking IGF-1 LR3 or DES variants with GH secretagogues or HGH | [Community] |
| subcutaneous injection | 10 mcg | once daily · 2-4 weeks | longevity-focused biohackers, older adults (40+) pursuing anti-aging and tissue repair | [Community] |
| subcutaneous injection | 20 mcg | once daily, post-workout on training days only · 6-8 weeks | recreational athletes and bodybuilders using training-day-only protocols | [Community] |
All studies (44)
- PMID 41010500 Human RCT
Pomegranate extract and IGF-1 in older adults - PMID 33236108 Human observational
Acromegaly monitoring and treatment assessment - PMID 34116443 Human observational
Schizophrenia (biomarker and treatment response) - PMID 34536657 Human observational
Postoperative delirium (biomarker) - PMID 35305249 Human observational
Bone health and fracture risk (beta-thalassemia major) - PMID 38526837 Human observational
Bone health and fracture risk (beta-thalassemia major) - PMID 40153319 Human observational
Fibromyalgia (biomarker) - PMID 40538800 Human observational
Pediatric metabolic abnormalities and hypertension (biomarker) - PMID 41039295 Human observational
Pediatric metabolic abnormalities and hypertension (biomarker) - PMID 31816435 Mixed
Effects of tamoxifen and metformin on IGF-1 levels - PMID 32013651 Mixed
Cardiovascular and endothelial biology (atherosclerosis, systemic sclerosis) - PMID 32142767 Mixed
Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) - PMID 32259791 Mixed
Exercise physiology and physical performance - PMID 33573338 Mixed
Skin aging and dermatological conditions (androgenetic alopecia, keloid, skin proteoglycan regulatio - PMID 34208601 Mixed
Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) - PMID 34469629 Mixed
Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) - PMID 35297369 Mixed
Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) - PMID 35331614 Mixed
Growth and height regulation in childhood and adulthood - PMID 35962006 Mixed
Neuroprotection and neurological disease (Parkinson's disease, ASD, neuroapoptosis) - PMID 36503467 Mixed
Neuroprotection and neurological disease (Parkinson's disease, ASD, neuroapoptosis) - PMID 37343154 Mixed
Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) - PMID 37496996 Mixed
Skin aging and dermatological conditions (androgenetic alopecia, keloid, skin proteoglycan regulatio - PMID 37671811 Mixed
Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) - PMID 38608792 Mixed
Effects of tamoxifen and metformin on IGF-1 levels - PMID 38941670 Mixed
Metabolic health — fatty liver disease (MASLD), insulin resistance, PCOS - PMID 39467934 Mixed
Neuroprotection and neurological disease (Parkinson's disease, ASD, neuroapoptosis) - PMID 39585426 Mixed
Cardiovascular and endothelial biology (atherosclerosis, systemic sclerosis) - PMID 40573144 Mixed
Exercise physiology and physical performance - PMID 41017432 Mixed
Growth and height regulation in childhood and adulthood - PMID 41184420 Mixed
Cancer biology (prostate, breast, colorectal, hepatocellular, multiple myeloma, gastric) - PMID 41534734 Mixed
Neuroprotection and neurological disease (Parkinson's disease, ASD, neuroapoptosis) - PMID 41796683 Mixed
Metabolic health — fatty liver disease (MASLD), insulin resistance, PCOS - PMID 41905437 Mixed
Neuroprotection and neurological disease (Parkinson's disease, ASD, neuroapoptosis) - PMID 31990681 Animal studies only
Polycystic kidney disease (ADPKD) - PMID 33557137
IGF-1 is described as a popular doping agent in sport with many high-profile doping cases; detection is complicated by IGFBPs reducing immunoreactive IGF-1 leve - PMID 33637845 In vitro only
Retinal and ocular biology (RPE metabolism, Müller glial cell glucose uptake, posterior capsular opa - PMID 33895582 Animal studies only
Wound healing and tissue regeneration - PMID 34452353
In chronic inflammatory conditions, inhibition of the GH-IGF-1 axis contributes to skeletal muscle atrophy and cachexia. - PMID 35388142 Animal studies only
Wound healing and tissue regeneration - PMID 39357179
The IGF-1/IGF-1R signaling pathway is associated with TNBC pathophysiology and therapy resistance; combination therapy strategies are being explored to overcome - PMID 39769402 In vitro only
Retinal and ocular biology (RPE metabolism, Müller glial cell glucose uptake, posterior capsular opa - PMID 41108835
In prolactinoma patients treated with cabergoline, IGF-1 levels showed significant reductions with longer treatment duration (≥18 months) and higher cumulative - PMID 41153350
- PMID 41294378
IGF-1 promoted IGF-1-driven invasion and migration in triple-negative breast cancer cells via PI3K/Akt/β-catenin axis activation.